Browse MAPK8

Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF00069 Protein kinase domain
Function

Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock (PubMed:22441692). Phosphorylates the heat shock transcription factor HSF1, suppressing HSF1-induced transcriptional activity (PubMed:10747973). ; FUNCTION: JNK1 isoforms display different binding patterns: beta-1 preferentially binds to c-Jun, whereas alpha-1, alpha-2, and beta-2 have a similar low level of binding to both c-Jun or ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms.

> Gene Ontology
 
Biological Process GO:0001844 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006476 protein deacetylation
GO:0006839 mitochondrial transport
GO:0006914 autophagy
GO:0007006 mitochondrial membrane organization
GO:0007254 JNK cascade
GO:0007258 JUN phosphorylation
GO:0007623 circadian rhythm
GO:0008637 apoptotic mitochondrial changes
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009612 response to mechanical stimulus
GO:0010506 regulation of autophagy
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0016236 macroautophagy
GO:0016241 regulation of macroautophagy
GO:0016570 histone modification
GO:0016575 histone deacetylation
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0031056 regulation of histone modification
GO:0031063 regulation of histone deacetylation
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0032091 negative regulation of protein binding
GO:0032496 response to lipopolysaccharide
GO:0035601 protein deacylation
GO:0035794 positive regulation of mitochondrial membrane permeability
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042752 regulation of circadian rhythm
GO:0043393 regulation of protein binding
GO:0046902 regulation of mitochondrial membrane permeability
GO:0048511 rhythmic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051204 protein insertion into mitochondrial membrane
GO:0051205 protein insertion into membrane
GO:0051403 stress-activated MAPK cascade
GO:0070585 protein localization to mitochondrion
GO:0071214 cellular response to abiotic stimulus
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071260 cellular response to mechanical stimulus
GO:0071396 cellular response to lipid
GO:0071496 cellular response to external stimulus
GO:0072655 establishment of protein localization to mitochondrion
GO:0072657 protein localization to membrane
GO:0090045 positive regulation of deacetylase activity
GO:0090150 establishment of protein localization to membrane
GO:0090311 regulation of protein deacetylation
GO:0090559 regulation of membrane permeability
GO:0097345 mitochondrial outer membrane permeabilization
GO:0098732 macromolecule deacylation
GO:1900739 regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway
GO:1900740 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway
GO:1901028 regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway
GO:1901030 positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway
GO:1902108 regulation of mitochondrial membrane permeability involved in apoptotic process
GO:1902110 positive regulation of mitochondrial membrane permeability involved in apoptotic process
GO:1902275 regulation of chromatin organization
GO:1902686 mitochondrial outer membrane permeabilization involved in programmed cell death
GO:1903747 regulation of establishment of protein localization to mitochondrion
GO:1903749 positive regulation of establishment of protein localization to mitochondrion
GO:1903829 positive regulation of cellular protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:2001233 regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004705 JUN kinase activity
GO:0004707 MAP kinase activity
GO:0005057 receptor signaling protein activity
GO:0016909 SAP kinase activity
GO:0035033 histone deacetylase regulator activity
GO:0042826 histone deacetylase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04024 cAMP signaling pathway
hsa04068 FoxO signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04140 Regulation of autophagy
hsa04141 Protein processing in endoplasmic reticulum
hsa04210 Apoptosis
hsa04310 Wnt signaling pathway
hsa04380 Osteoclast differentiation
hsa04510 Focal adhesion
hsa04530 Tight junction
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04668 TNF signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04723 Retrograde endocannabinoid signaling
hsa04728 Dopaminergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04910 Insulin signaling pathway
hsa04912 GnRH signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04917 Prolactin signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-114452: Activation of BH3-only proteins
R-HSA-111446: Activation of BIM and translocation to mitochondria
R-HSA-139910: Activation of BMF and translocation to mitochondria
R-HSA-450341: Activation of the AP-1 family of transcription factors
R-HSA-109581: Apoptosis
R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE
R-HSA-1500931: Cell-Cell communication
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-5693606: DNA Double Strand Break Response
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-376172: DSCAM interactions
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-109606: Intrinsic Pathway for Apoptosis
R-HSA-450321: JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-450282: MAPK targets/ Nuclear events mediated by MAP kinases
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-193648: NRAGE signals death through JNK
R-HSA-205043: NRIF signals cell death from the nucleus
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-5357801: Programmed Cell Death
R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAPK8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MAPK8 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23935194MelanomaPromote immunityWe also show that the AICD in TCReng CD4 T cells is a death receptor-independent process and that JNK and p53 play critical roles in this process as pharmacological inhibitors targeting JNK activation and p-53-mediated transcription-independent mitochondria-centric death cascade rescued a significant fraction of TCReng CD4 T cells from undergoing AICD without affecting their effector function.
16237070Melanoma; LymphomaPromote immunity (T cell function)JNK1 is essential for CD8+ T cell-mediated tumor immune surveillance. JNK1-/- CD8+ T cells have an intrinsic defect in early IFN-gamma gene transcription and production after activation by either anti-CD3/anti-CD28 Abs or dendritic cells loaded with specific Ag in vitro. The impaired IFN-gamma production in JNK1-/- CD8+ T cells is associated with reduced expression of both T-bet and Eomesodermin, indicating that JNK1 regulates the transcription program of CD8+ T cells. Finally, JNK1-/- CD8+ T cells showed reduced perforin expression and impaired CTL function.
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAPK8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAPK8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1050.673
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1550.888
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0630.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2970.365
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5240.718
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0090.996
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0620.825
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0950.927
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0160.989
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.9120.432
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1930.9
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0320.57
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAPK8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAPK8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAPK8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAPK8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAPK8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAPK8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAPK8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAPK8
Namemitogen-activated protein kinase 8
Aliases JNK; JNK1; SAPK1; JUN N-terminal kinase; PRKM8; JNK-46; JNK1A2; JNK21B1/2; SAPK1c; MAP kinase 8; c-Jun N-ter ......
Chromosomal Location10q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAPK8 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MAPK8.
ID Name Drug Type Targets #Targets
DB017822,6-Dihydroanthra/1,9-Cd/Pyrazol-6-OneSmall MoleculeMAPK10, MAPK8, MAPK8IP1, TTK4
DB072186-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONESmall MoleculeMAPK8, MAPK8IP12
DB072682-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDESmall MoleculeMAPK81
DB07272N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDESmall MoleculeMAPK8, MAPK8IP12
DB072765-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDESmall MoleculeMAPK8, MAPK8IP12
DB078452-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamideSmall MoleculeMAPK81